Biomarkers for Human Heart Failure (Biomarkers)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03905252|
Recruitment Status : Recruiting
First Posted : April 5, 2019
Last Update Posted : June 2, 2020
|Condition or disease||Intervention/treatment|
|CHF||Other: sample analysis|
Schematic Design of the Study: Single blood draw, one random urine and 24-hr urine collection from hospitalized patients with chronic/acute heart failure and/or STEMI-NSTEMI. If there should be a subsequent hospitalization,another collection of a 45 ml blood sample, random urine and one 24-hour urine collection may be completed if indicated at initial hospitalization.
The purpose of this study is to attempt to establish the various ranges of proteins that can be assayed from the plasma and urine of patients with all classes of heart failure and MI (myocardial infarction). Follow-up hospitalizations may result in another 45 ml blood draw, random urine and 24-hr. urine collection to evaluate the outcome of the heart failure treatment used with the previous hospitalization, if indicated in consent. A history review will be necessary as well.
|Study Type :||Observational|
|Estimated Enrollment :||800 participants|
|Official Title:||Biomarkers for Human Heart Failure|
|Study Start Date :||August 2009|
|Estimated Primary Completion Date :||December 2021|
|Estimated Study Completion Date :||December 2022|
- Other: sample analysis
blood, Random urine sample and 24-hour urine samples
- uAGT levels in high-risk chronic HF patients [ Time Frame: 10 years ]This study will provide new knowledge of the pathology and outcomes predicted by the use of uAGT in symptomatic chronic HF patients at high risk for future hospitalization and death.
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03905252
|Contact: Seethalakshmi R Iyer, MSemail@example.com|
|Contact: Emery (John) van Hook||507-284-4838||VanHook.Emery@mayo.edu|
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|
|Contact: Seethalakshmi Iyer, MS 507-284-4838 firstname.lastname@example.org|
|Contact: Emery (John) Van Hook 507-284-4838 VanHook.Emery@mayo.edu|
|Principal Investigator: John C Burnett, M.D.|
|Principal Investigator:||John C Burnett, M.D.||Mayo Foundation|